$13MSeed, 17 February 2026
Seed funds advance GMX-101, a retinal cell therapy for geographic atrophy, alongside a first pharma collaboration.
- Amount
- $13M
- Stage
- Seed
- Announced
- 17 February 2026
- Lead
- Safar Partners
- Other investors
- HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels
- Use of funds
- Seed funds advance GMX-101, a retinal cell therapy for geographic atrophy, alongside a first pharma collaboration.
- Checked
- Amount and date matched across 2 press sources
- Sources
- GelMEDIX closes $13M seed for vision restoration biotech pulse2.com
GelMEDIX closes $13M seed for vision restoration biotech pulse2.com